ATE370728T1 - Antagonisten des gardos-kanals - Google Patents

Antagonisten des gardos-kanals

Info

Publication number
ATE370728T1
ATE370728T1 AT00907283T AT00907283T ATE370728T1 AT E370728 T1 ATE370728 T1 AT E370728T1 AT 00907283 T AT00907283 T AT 00907283T AT 00907283 T AT00907283 T AT 00907283T AT E370728 T1 ATE370728 T1 AT E370728T1
Authority
AT
Austria
Prior art keywords
antagonists
gardos channel
gardos
channel
Prior art date
Application number
AT00907283T
Other languages
German (de)
English (en)
Inventor
Grant Mcnaughton-Smith
Gregory Rigdon
Jonathan Stocker
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Application granted granted Critical
Publication of ATE370728T1 publication Critical patent/ATE370728T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00907283T 1999-02-23 2000-02-10 Antagonisten des gardos-kanals ATE370728T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists

Publications (1)

Publication Number Publication Date
ATE370728T1 true ATE370728T1 (de) 2007-09-15

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907283T ATE370728T1 (de) 1999-02-23 2000-02-10 Antagonisten des gardos-kanals

Country Status (16)

Country Link
US (1) US6288122B1 (https=)
EP (1) EP1158971B1 (https=)
JP (2) JP4038337B2 (https=)
KR (1) KR100705726B1 (https=)
CN (1) CN1193748C (https=)
AP (1) AP1465A (https=)
AT (1) ATE370728T1 (https=)
AU (1) AU762039B2 (https=)
BR (1) BR0008416A (https=)
CA (1) CA2371857C (https=)
DE (1) DE60036093T2 (https=)
ES (1) ES2291191T3 (https=)
HK (1) HK1045262B (https=)
IL (2) IL145012A0 (https=)
OA (1) OA11838A (https=)
WO (1) WO2000050026A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
JP4394451B2 (ja) * 2002-01-04 2010-01-06 ニューロサーチ、アクティーゼルスカブ カリウムチャネルモジュレーター
US20040029771A1 (en) * 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
WO2005003094A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
US7709533B2 (en) * 2005-02-01 2010-05-04 Icagen, Inc. Imines as ion channel modulators
KR20080086511A (ko) * 2005-12-20 2008-09-25 이카겐, 인코포레이티드 트리아릴 메탄 화합물을 이용한 치료 방법
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
ES2358564T3 (es) 2007-08-24 2011-05-11 Neurosearch A/S Derivados de carbonilamino útiles para el tratamiento de una enfermedad inflamatoria intestinal.
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
CA2720824C (en) 2008-04-09 2021-09-14 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
CN102272152B (zh) 2008-11-10 2014-05-28 贝林格尔.英格海姆国际有限公司 通过中电导钙激活钾通道调控细胞-细胞融合的组合物及方法
WO2016134353A1 (en) * 2015-02-20 2016-08-25 Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) * 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
WO2018081018A1 (en) * 2016-10-25 2018-05-03 Paracelsus Neuroscience Llc Use of senicapoc for treatment of neuropathic pain
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
CN112020353A (zh) * 2019-03-29 2020-12-01 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US12186286B2 (en) * 2019-07-29 2025-01-07 Paracelsus Neuroscience Llc Use of senicapoc for treatment of stroke
WO2022015893A2 (en) * 2020-07-14 2022-01-20 Adimabio Llc Compositions comprising gardos channel antagonists and their uses
EP4259130B1 (en) * 2020-12-11 2026-03-04 Sanquin IP B.V. Gardos channel inhibitor or other agents for use in the treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
AU732881C (en) 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof

Also Published As

Publication number Publication date
AU2880700A (en) 2000-09-14
JP2007262075A (ja) 2007-10-11
CN1193748C (zh) 2005-03-23
HK1045262A1 (en) 2002-11-22
JP2002537331A (ja) 2002-11-05
WO2000050026A1 (en) 2000-08-31
CA2371857A1 (en) 2000-08-31
CN1344158A (zh) 2002-04-10
JP4038337B2 (ja) 2008-01-23
KR100705726B1 (ko) 2007-04-11
EP1158971A1 (en) 2001-12-05
EP1158971A4 (en) 2003-04-16
OA11838A (en) 2005-08-22
ES2291191T3 (es) 2008-03-01
DE60036093D1 (de) 2007-10-04
US6288122B1 (en) 2001-09-11
HK1045262B (zh) 2005-07-29
IL145012A (en) 2006-12-10
CA2371857C (en) 2008-07-29
AP1465A (en) 2005-09-22
IL145012A0 (en) 2002-06-30
AU762039B2 (en) 2003-06-19
AP2001002268A0 (en) 2001-09-30
BR0008416A (pt) 2002-01-29
DE60036093T2 (de) 2008-05-15
KR20020002393A (ko) 2002-01-09
EP1158971B1 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
ATE512594T1 (de) Verbesserung des zustandes älterer haustiere
ATE370728T1 (de) Antagonisten des gardos-kanals
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
ATE317652T1 (de) Zahnbürste
ATE261679T1 (de) Zahnbürste
DE59902843D1 (de) Brauseformulierungen
ATE264633T1 (de) Zahnbürste
DE10084428T1 (de) Zahnbürste
ATE502923T1 (de) Amid-verbindungen
EE05020B1 (et) Glburiidi ravimkoostis
DE60007530D1 (de) Oral wirksame androgene
DE50009595D1 (de) Zahnbürste
DK1022396T3 (da) Bruserkombination
DE50015795D1 (de) Sektionaltor
DE50006709D1 (de) Zahnbürste
PT1287095E (pt) Mistura de gasolina-oxigenato
ES1045691Y (es) Ducha
ID30381A (id) Penggunaan arilalkanoilpiridazina
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
ATE252549T1 (de) Aminobutyronitril mischung
ATA36099A (de) Stoffgemisch
ITMI20000412A0 (it) Doccia
DK1133361T3 (da) Brusehoved
FIU990082U0 (fi) Siemenseos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1158971

Country of ref document: EP